普洛药业(000739.SZ)头孢地尼胶囊获药品注册证书

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) announced that its subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration [1] Group 1: Product Information - Cefdinir capsules are indicated for infections caused by bacteria sensitive to Cefdinir, including strains of Staphylococcus, Streptococcus, and others [1] - The specific infections treated by Cefdinir capsules include pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, sinusitis, pyelonephritis, cystitis, gonococcal urethritis, and various skin and soft tissue infections [1]